76 related articles for article (PubMed ID: 12702897)
21. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
22. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial.
Stein DJ; Westenberg HG; Yang H; Li D; Barbato LM
Int J Neuropsychopharmacol; 2003 Dec; 6(4):317-23. PubMed ID: 14604447
[TBL] [Abstract][Full Text] [Related]
23. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
24. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
Pollack MH; Tiller J; Xie F; Trivedi MH
J Clin Psychopharmacol; 2008 Jun; 28(3):308-16. PubMed ID: 18480688
[TBL] [Abstract][Full Text] [Related]
25. An open-label, flexible-dose study of memantine in major depressive disorder.
Ferguson JM; Shingleton RN
Clin Neuropharmacol; 2007; 30(3):136-44. PubMed ID: 17545748
[TBL] [Abstract][Full Text] [Related]
26. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
27. A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania.
Eden Evins A; Demopulos C; Nierenberg A; Culhane MA; Eisner L; Sachs G
Bipolar Disord; 2006 Feb; 8(1):75-80. PubMed ID: 16411983
[TBL] [Abstract][Full Text] [Related]
28. An open-label study of levetiracetam for the treatment of social anxiety disorder.
Simon NM; Worthington JJ; Doyle AC; Hoge EA; Kinrys G; Fischmann D; Link N; Pollack MH
J Clin Psychiatry; 2004 Sep; 65(9):1219-22. PubMed ID: 15367048
[TBL] [Abstract][Full Text] [Related]
29. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.
Baldwin D; Bobes J; Stein DJ; Scharwächter I; Faure M
Br J Psychiatry; 1999 Aug; 175():120-6. PubMed ID: 10627793
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid.
Bellino S; Bozzatello P; Rocca G; Bogetto F
J Psychopharmacol; 2014 Feb; 28(2):125-32. PubMed ID: 24196948
[TBL] [Abstract][Full Text] [Related]
31. A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder.
Careri JM; Draine AE; Hanover R; Liebowitz MR
Prim Care Companion CNS Disord; 2015; 17(6):. PubMed ID: 27057414
[TBL] [Abstract][Full Text] [Related]
32. Mirtazapine in social anxiety disorder: a pilot study.
Van Veen JF; Van Vliet IM; Westenberg HG
Int Clin Psychopharmacol; 2002 Nov; 17(6):315-7. PubMed ID: 12409686
[TBL] [Abstract][Full Text] [Related]
33. Imipramine in the treatment of social phobia.
Simpson HB; Schneier FR; Campeas RB; Marshall RD; Fallon BA; Davies S; Klein DF; Liebowitz MR
J Clin Psychopharmacol; 1998 Apr; 18(2):132-5. PubMed ID: 9555598
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the clinical global impression scale among individuals with social anxiety disorder.
Zaider TI; Heimberg RG; Fresco DM; Schneier FR; Liebowitz MR
Psychol Med; 2003 May; 33(4):611-22. PubMed ID: 12785463
[TBL] [Abstract][Full Text] [Related]
35. [Psychodynamic group treatment for generalized social phobia].
Knijnik DZ; Kapczinski F; Chachamovich E; Margis R; Eizirik CL
Braz J Psychiatry; 2004 Jun; 26(2):77-81. PubMed ID: 15517057
[TBL] [Abstract][Full Text] [Related]
36. Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials.
de Menezes GB; Coutinho ES; Fontenelle LF; Vigne P; Figueira I; Versiani M
Psychopharmacology (Berl); 2011 May; 215(1):1-11. PubMed ID: 21181129
[TBL] [Abstract][Full Text] [Related]
37. Recognizing the patient with social anxiety disorder.
Ballenger JC
Int Clin Psychopharmacol; 2000 Jul; 15 Suppl 1():S1-5. PubMed ID: 10994676
[TBL] [Abstract][Full Text] [Related]
38. Resistant social anxiety disorder response to Escitalopram.
Pallanti S; Quercioli L
Clin Pract Epidemiol Ment Health; 2006 Dec; 2():35. PubMed ID: 17166264
[TBL] [Abstract][Full Text] [Related]
39. Effect of valproate on plasma levels of interleukin-6 in healthy male humans.
Shiah IS; Yatham LN; Yeh CB; Ravindran AV
Int Clin Psychopharmacol; 2005 Nov; 20(6):295-8. PubMed ID: 16192836
[TBL] [Abstract][Full Text] [Related]
40. Valproate in anxiety and withdrawal syndromes.
Roy-Byrne PP; Ward NG; Donnelly PJ
J Clin Psychiatry; 1989 Mar; 50 Suppl():44-8. PubMed ID: 2494160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
